Drug Approval | April 18, 2024
Jubilant Pharmova’s Roorkee unit gets VAI status
FDA has concluded that this inspection is 'closed'
FDA has concluded that this inspection is 'closed'
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The company will respond to the Warning Letter within the stipulated timelines
The facility will manufacture tablets, capsules, and injections for the oncology segment
The company is confident of addressing the concern raised by the USFDA
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
Subscribe To Our Newsletter & Stay Updated
